News articles about Novartis (NYSE:NVS) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novartis earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.9805131217458 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- BRIEF—Novartis files for Japanese approval of Kymriah (thepharmaletter.com)
- SYRIZA MPs request extension for Novartis report (ekathimerini.com)
- Novartis Q1 2018: Recent Sell-Off Seems Overdone (seekingalpha.com)
- Is Biopharma Investing Too Much In Cancer R&D? (finance.yahoo.com)
- Insider Buying: Novartis (NVS) Major Shareholder Purchases 766,666 Shares of Stock (americanbankingnews.com)
NVS traded down $0.61 on Tuesday, hitting $76.99. The company had a trading volume of 1,571,252 shares, compared to its average volume of 1,753,937. Novartis has a 1-year low of $75.62 and a 1-year high of $94.19. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.91 and a current ratio of 1.17. The firm has a market cap of $180,483.47, a P/E ratio of 16.01, a price-to-earnings-growth ratio of 1.76 and a beta of 0.74.
NVS has been the topic of several research analyst reports. JPMorgan Chase reaffirmed a “neutral” rating on shares of Novartis in a research note on Monday, April 9th. Deutsche Bank reaffirmed a “neutral” rating on shares of Novartis in a research note on Tuesday, April 10th. UBS reaffirmed a “neutral” rating on shares of Novartis in a research note on Monday, January 15th. Zacks Investment Research cut Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Finally, Nord/LB reiterated a “neutral” rating on shares of Novartis in a report on Wednesday, December 27th. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $87.51.
In other Novartis news, major shareholder Institutes For Biomed Novartis purchased 766,666 shares of the company’s stock in a transaction on Monday, April 23rd. The shares were bought at an average cost of $15.00 per share, with a total value of $11,499,990.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.01% of the company’s stock.
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.